SIO GENE THERAPIES INC. : Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Settlement FD Disclosure, Financial Statements and Exhibits (Form 8-K)
Section 1.02 Termination of a Material Definitive Agreement.
A summary of the material terms of the UMMS License Agreement has been included in our Quarterly Report on Form 10-Q for the fiscal quarter ended
filed with the
Item 2.02 Results of Operations and Financial Condition.
A copy of this press release is provided as Exhibit 99.1 to this report and is incorporated herein by reference. The disclosures set forth in this Section 2.02 and Exhibit 99.1 to this report are provided and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to requirements of this article. The information contained in this Section 2.02 and Exhibit 99.1 of this report shall not be deemed incorporated by reference in any other filing with the
Item 2.05 Costs associated with removal or disposal activities.
As part of these strategic decisions, we expect to incur aggregate costs estimated to be between approximately
Section 7.01 Disclosure of FD Rules.
A copy of this press release is provided as Exhibit 99.1 to this report and is incorporated herein by reference. The disclosures set forth in this Section 7.01 and Exhibit 99.1 to this report are provided and not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the responsibilities of This article. The information contained in this Section 7.01 and Exhibit 99.1 of this report shall not be deemed incorporated by reference in any other filing with the
This report contains forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “believe”, “would”, “plan”, “explore”, “expect”, “intend”, “estimate”, “may” and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding potential strategic alternatives focused on maximizing shareholder value and the related review process, costs associated with our planned operating activities, workforce reductions and capital preservation plans, expectations regarding the ability to obtain financing and expectations regarding licensing and commercial agreements including planned activities, timing and costs associated with the liquidation of clinical programs (including licensing agreements and manufacturing for GM1 and GM2) are looking to the future. All forward-looking statements are based on our management’s estimates and assumptions which, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those we expected. These risks and uncertainties include, among others, the impact of the COVID-19 pandemic on our operations; actual funds required for planned operating activities, including liquidation activities for clinical programs and exploration of strategic alternatives; costs and risks related to workforce reductions and capital conservation plans; the ability to explore and execute strategic alternatives; the ability to effectively scale down clinical programs and conduct required activities during phase-down processes; the outcome of interactions with regulators.
These statements are also subject to a number of important risks and uncertainties which are described in our most recent Quarterly Report on Form 10-Q filed with the
Item 9.01 Financial statements and supporting documents.
(d) Exhibits. Exhibit Number Description of Document 99.1 Press Release of
Sio Gene Therapies Inc., dated April 27, 2022, "Sio Gene Therapies Provides Corporate Update" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source